Lappoxo

Omeprazole, the active ingredient in Lappoxo, is a proton pump inhibitor presented as an oral formulation for oral use. It reduces gastric acid secretion and is employed to manage conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Lappoxo as a licensed, GDP‑compliant international pharmaceutical product, providing reliable access to hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and ensures consistent batch release for global distribution.

Omeprazole is indicated for acid‑related gastrointestinal disorders, acting to control excessive gastric acid production.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by maintaining a neutral gastric environment. - Helicobacter pylori eradication regimens: enhances antibiotic efficacy by suppressing acid production during combination therapy.

Omeprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually transient. - Abdominal pain: cramping or discomfort. - Nausea: occasional upset stomach. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reaction (anaphylaxis): rash, swelling, airway compromise. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment. - Hepatic enzyme elevation: significant increase in ALT/AST levels.

When prescribing omeprazole, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal and hepatic function: adjust use in patients with severe impairment. - Evaluate CYP2C19 metabolism status: poor metabolizers may have higher exposure. - Avoid long‑term use without reassessment: prolonged therapy can increase fracture risk. - Monitor for signs of infection: especially C. difficile‑associated diarrhea. - Use with caution in elderly patients: higher susceptibility to adverse events. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can alter the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: markedly decreased antiviral exposure, compromising HIV therapy. - HIV protease inhibitors (e.g., ritonavir): reduced efficacy due to increased gastric pH.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, requiring dose adjustment. - Phenytoin: decreased phenytoin concentrations, may need therapeutic monitoring. - Ketoconazole or itraconazole: reduced antifungal absorption, consider alternative agents.